[SARS CoV-2/COVID-19: Evidence-Based Recommendation on Diagnosis and Therapy].
Identifieur interne : 000010 ( PubMed/Checkpoint ); précédent : 000009; suivant : 000011[SARS CoV-2/COVID-19: Evidence-Based Recommendation on Diagnosis and Therapy].
Auteurs : Berthold Bein ; Martin Bachmann ; Susanne Huggett ; Petra WegermannSource :
- Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS [ 1439-1074 ] ; 2020.
Descripteurs français
- KwdFr :
- Facteurs de risque, Humains, Indice de gravité médicale, Infections à coronavirus (), Infections à coronavirus (diagnostic), Médecine factuelle, Oxygénation extracorporelle sur oxygénateur à membrane (), Pandémies, Pneumopathie virale (), Pneumopathie virale (diagnostic), Ventilation artificielle (), Vêtements de protection.
- MESH :
- diagnostic : Infections à coronavirus, Pneumopathie virale.
- Facteurs de risque, Humains, Indice de gravité médicale, Infections à coronavirus, Médecine factuelle, Oxygénation extracorporelle sur oxygénateur à membrane, Pandémies, Pneumopathie virale, Ventilation artificielle, Vêtements de protection.
English descriptors
- KwdEn :
- Betacoronavirus, Coronavirus Infections (diagnosis), Coronavirus Infections (therapy), Evidence-Based Medicine, Extracorporeal Membrane Oxygenation (methods), Humans, Pandemics, Pneumonia, Viral (diagnosis), Pneumonia, Viral (therapy), Protective Clothing, Respiration, Artificial (methods), Risk Factors, Severity of Illness Index.
- MESH :
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- methods : Extracorporeal Membrane Oxygenation, Respiration, Artificial.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, Evidence-Based Medicine, Humans, Pandemics, Protective Clothing, Risk Factors, Severity of Illness Index.
Abstract
COVID-19, a new viral disease affecting primarily the respiratory system and the lung, has caused a pandemic with serious challenges to health systems around the world. In about 20% of patients, severe symptoms occur after a mean incubation period of 5 - 6 days; 5% of patients need intensive care therapy. Morbidity is about 1 - 2%. Protecting health care workers is of paramount importance in order to prevent hospital acquired infections. Therefore, during all procedures associated with aerosol production, a personal safety equipment consisting of a FFP2/FFP3 (N95) respiratory mask, gloves, safety glasses and a waterproof overall should be used. Therapy is based on established recommendations issued for patients with acute lung injury (ARDS). Lung protective ventilation, prone position, restrictive fluid management and an adequate management of organ failures are the mainstays of therapy. In case of fulminant lung failure, veno-venous extracorporeal membrane oxygenation may be used as a rescue in experienced centres. New, experimental therapies evolve with ever increasing frequency; currently, however, there is no evidence based recommendation possible. If off-label and compassionate use of these drugs is considered, an individual benefit-risk assessment is necessary, since serious side effects have been reported.
DOI: 10.1055/a-1146-8674
PubMed: 32274773
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32274773Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[SARS CoV-2/COVID-19: Evidence-Based Recommendation on Diagnosis and Therapy].</title><author><name sortKey="Bein, Berthold" sort="Bein, Berthold" uniqKey="Bein B" first="Berthold" last="Bein">Berthold Bein</name></author><author><name sortKey="Bachmann, Martin" sort="Bachmann, Martin" uniqKey="Bachmann M" first="Martin" last="Bachmann">Martin Bachmann</name></author><author><name sortKey="Huggett, Susanne" sort="Huggett, Susanne" uniqKey="Huggett S" first="Susanne" last="Huggett">Susanne Huggett</name></author><author><name sortKey="Wegermann, Petra" sort="Wegermann, Petra" uniqKey="Wegermann P" first="Petra" last="Wegermann">Petra Wegermann</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32274773</idno><idno type="pmid">32274773</idno><idno type="doi">10.1055/a-1146-8674</idno><idno type="wicri:Area/PubMed/Corpus">000246</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000246</idno><idno type="wicri:Area/PubMed/Curation">000246</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000246</idno><idno type="wicri:Area/PubMed/Checkpoint">000010</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000010</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[SARS CoV-2/COVID-19: Evidence-Based Recommendation on Diagnosis and Therapy].</title><author><name sortKey="Bein, Berthold" sort="Bein, Berthold" uniqKey="Bein B" first="Berthold" last="Bein">Berthold Bein</name></author><author><name sortKey="Bachmann, Martin" sort="Bachmann, Martin" uniqKey="Bachmann M" first="Martin" last="Bachmann">Martin Bachmann</name></author><author><name sortKey="Huggett, Susanne" sort="Huggett, Susanne" uniqKey="Huggett S" first="Susanne" last="Huggett">Susanne Huggett</name></author><author><name sortKey="Wegermann, Petra" sort="Wegermann, Petra" uniqKey="Wegermann P" first="Petra" last="Wegermann">Petra Wegermann</name></author></analytic><series><title level="j">Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS</title><idno type="eISSN">1439-1074</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (therapy)</term><term>Evidence-Based Medicine</term><term>Extracorporeal Membrane Oxygenation (methods)</term><term>Humans</term><term>Pandemics</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (therapy)</term><term>Protective Clothing</term><term>Respiration, Artificial (methods)</term><term>Risk Factors</term><term>Severity of Illness Index</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Facteurs de risque</term><term>Humains</term><term>Indice de gravité médicale</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (diagnostic)</term><term>Médecine factuelle</term><term>Oxygénation extracorporelle sur oxygénateur à membrane ()</term><term>Pandémies</term><term>Pneumopathie virale ()</term><term>Pneumopathie virale (diagnostic)</term><term>Ventilation artificielle ()</term><term>Vêtements de protection</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Extracorporeal Membrane Oxygenation</term><term>Respiration, Artificial</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Evidence-Based Medicine</term><term>Humans</term><term>Pandemics</term><term>Protective Clothing</term><term>Risk Factors</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs de risque</term><term>Humains</term><term>Indice de gravité médicale</term><term>Infections à coronavirus</term><term>Médecine factuelle</term><term>Oxygénation extracorporelle sur oxygénateur à membrane</term><term>Pandémies</term><term>Pneumopathie virale</term><term>Ventilation artificielle</term><term>Vêtements de protection</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">COVID-19, a new viral disease affecting primarily the respiratory system and the lung, has caused a pandemic with serious challenges to health systems around the world. In about 20% of patients, severe symptoms occur after a mean incubation period of 5 - 6 days; 5% of patients need intensive care therapy. Morbidity is about 1 - 2%. Protecting health care workers is of paramount importance in order to prevent hospital acquired infections. Therefore, during all procedures associated with aerosol production, a personal safety equipment consisting of a FFP2/FFP3 (N95) respiratory mask, gloves, safety glasses and a waterproof overall should be used. Therapy is based on established recommendations issued for patients with acute lung injury (ARDS). Lung protective ventilation, prone position, restrictive fluid management and an adequate management of organ failures are the mainstays of therapy. In case of fulminant lung failure, veno-venous extracorporeal membrane oxygenation may be used as a rescue in experienced centres. New, experimental therapies evolve with ever increasing frequency; currently, however, there is no evidence based recommendation possible. If off-label and compassionate use of these drugs is considered, an individual benefit-risk assessment is necessary, since serious side effects have been reported.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32274773</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-1074</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS</Title><ISOAbbreviation>Anasthesiol Intensivmed Notfallmed Schmerzther</ISOAbbreviation></Journal><ArticleTitle>[SARS CoV-2/COVID-19: Evidence-Based Recommendation on Diagnosis and Therapy].</ArticleTitle><Pagination><MedlinePgn>257-265</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/a-1146-8674</ELocationID><Abstract><AbstractText>COVID-19, a new viral disease affecting primarily the respiratory system and the lung, has caused a pandemic with serious challenges to health systems around the world. In about 20% of patients, severe symptoms occur after a mean incubation period of 5 - 6 days; 5% of patients need intensive care therapy. Morbidity is about 1 - 2%. Protecting health care workers is of paramount importance in order to prevent hospital acquired infections. Therefore, during all procedures associated with aerosol production, a personal safety equipment consisting of a FFP2/FFP3 (N95) respiratory mask, gloves, safety glasses and a waterproof overall should be used. Therapy is based on established recommendations issued for patients with acute lung injury (ARDS). Lung protective ventilation, prone position, restrictive fluid management and an adequate management of organ failures are the mainstays of therapy. In case of fulminant lung failure, veno-venous extracorporeal membrane oxygenation may be used as a rescue in experienced centres. New, experimental therapies evolve with ever increasing frequency; currently, however, there is no evidence based recommendation possible. If off-label and compassionate use of these drugs is considered, an individual benefit-risk assessment is necessary, since serious side effects have been reported.</AbstractText><CopyrightInformation>Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="N"><LastName>Bein</LastName><ForeName>Berthold</ForeName><Initials>B</Initials></Author><Author ValidYN="Y" EqualContrib="N"><LastName>Bachmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y" EqualContrib="N"><LastName>Huggett</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y" EqualContrib="N"><LastName>Wegermann</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>SARS-CoV-2/COVID-19: Empfehlungen zu Diagnostik und Therapie.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Anasthesiol Intensivmed Notfallmed Schmerzther</MedlineTA><NlmUniqueID>9109478</NlmUniqueID><ISSNLinking>0939-2661</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011481" MajorTopicYN="N">Protective Clothing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Der Übersichtsartikel ist als praktische Handreichung für alle gedacht, die COVID-19-Patienten behandeln bzw. in nächster Zeit behandeln werden, und fasst das derzeit verfügbare Wissen zu Diagnostik und Therapie zusammen. Zusätzlich werden auch neue und experimentelle Therapien bewertet, soweit dazu zumindest Einzelfallberichte vorliegen.</AbstractText></OtherAbstract><CoiStatement>Prof. Bein hat Honorare für Vorträge und Beratertätigkeit von Pulsion/Maquet, Edwards Life Sciences und Cytosorbents erhalten. Die anderen Autorinnen/Autoren geben an, dass keine Interessenkonflikte bestehen.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32274773</ArticleId><ArticleId IdType="doi">10.1055/a-1146-8674</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Bachmann, Martin" sort="Bachmann, Martin" uniqKey="Bachmann M" first="Martin" last="Bachmann">Martin Bachmann</name><name sortKey="Bein, Berthold" sort="Bein, Berthold" uniqKey="Bein B" first="Berthold" last="Bein">Berthold Bein</name><name sortKey="Huggett, Susanne" sort="Huggett, Susanne" uniqKey="Huggett S" first="Susanne" last="Huggett">Susanne Huggett</name><name sortKey="Wegermann, Petra" sort="Wegermann, Petra" uniqKey="Wegermann P" first="Petra" last="Wegermann">Petra Wegermann</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000010 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000010 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:32274773
|texte= [SARS CoV-2/COVID-19: Evidence-Based Recommendation on Diagnosis and Therapy].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32274773" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |